Gyre Therapeutics (GYRE) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about GYRE filings

Are insiders buying or selling Gyre Therapeutics Inc. (GYRE) stock?

Neither. Gyre Therapeutics Inc. (GYRE) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GYRE recently?

None. No member of Congress disclosed a GYRE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GYRE smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on GYRE

Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales
3 of 3 on scheduled plans. Form 4 filings.
Congress
No recent politician filings found
Funds
No recent fund filings found
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about GYRE filings

Are insiders buying or selling Gyre Therapeutics Inc. (GYRE) stock?

Neither. Gyre Therapeutics Inc. (GYRE) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GYRE recently?

None. No member of Congress disclosed a GYRE trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GYRE smart-money data?

Insiders

What insiders are doing

3 trades · 6 mo

Sells (3)

YW
Ye Weiguo
Chief Operating Officer · May 27
YW
Ye Weiguo
Chief Operating Officer · May 22
YW
Ye Weiguo
Chief Operating Officer · May 20

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 5, 2026

Earnings came in 126.7% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 5, 2026

Period ending

Sep 30, 2026

Earnings per share

$0.04+126.67% beat

-$0.15 expected

Revenue

$32.9M

SEC filing

Next report

What the street expects next

Estimates as of Nov 12, 2026

EPS expected

-$0.12

-$0.20 to -$0.05

Revenue expected

$29.5M

3 analysts

Last 30 days

1up2down

Analysts cutting estimates

Estimate drift

0.04

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 5, 2026	$0.04est. -$0.15	+126.67%beat	$32.9MSEC filing	+0.7%from $32.7M
Jun 30, 2026Reported Aug 7, 2026	-$0.12est. -$0.08	-$0.04miss	$29.1MSEC filing	-2.1%from $29.7M
Mar 31, 2026Reported May 7, 2026	-$0.10est. -$0.07	-$0.03miss	$22.5MSEC filing	+2.1%from $22.1M
Dec 31, 2025Reported Mar 12, 2026	$0.05est. $0.05	+$0.00in line	CNY 37.2MAlpha Vantage	+33.4%from CNY 27.9M
Sep 30, 2025Reported Nov 7, 2025	$0.03est. -$0.02	+$0.05beat	$32.7MSEC filing	+28.3%from $25.5M
Jun 30, 2025Reported Aug 11, 2025	$0.00est. $0.03	-$0.03miss	$29.7MSEC filing	+17.9%from $25.2M
Mar 31, 2025Reported May 9, 2025	$0.00est. $0.03	-$0.03miss	$22.1MSEC filing	-18.8%from $27.2M
Dec 31, 2024Reported Mar 17, 2025	-$0.00est. $0.04	-$0.04miss	CNY 27.9MAlpha Vantage	+2.7%from CNY 27.1M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $4.63
High: $4.63
Low: $4.22
Prev close: $4.65
52-wk high: $9.14
52-wk low: $3.97
Mkt cap: $470.6M
ROE: -17.2%
Fwd P/E: 188.7x
Beta: 4.92
P/S: 4.3x
P/B: 4.3x
Profit margin: -22.7%
Op margin: -16.6%

Sep 2026 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Sep 2026

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$32.9M
Cost of what it soldCost of revenue	$1.9M
Gross profit	$31.0M
What it spent
Research and development	$8.5M
Sales and adminSelling, general and administrative	$8.9M
Other operating costsOperating costs not itemised in the filing's summary	$15.1M
Total operating expenses	$32.5M
What was left
Operating profitOperating income	-$1.5M
Profit before tax	-$1.7M
TaxIncome tax expense	$733.0K
Net profitNet income	-$4.1M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$1.7M

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

36balanced

20D volatility

159%annualized

52-week range

$4.23

$3.97$9.14

20D support

$3.97recent floor

20D resistance

$7.10recent ceiling

Returns

5D -4.7%20D -37.0%60D -37.9%

Price vs moving averages

SMA20 -23.6%SMA50 -34.2%SMA200 -38.4%

Volume pace

0.95xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 5, 2026

$0.04est. -$0.15

+126.67%

$32.9MSEC filing

+0.7%from $32.7M

Jun 30, 2026Aug 7, 2026

-$0.12est. -$0.08

-$0.04

$29.1MSEC filing

-2.1%from $29.7M

Mar 31, 2026May 7, 2026

-$0.10est. -$0.07

-$0.03

$22.5MSEC filing

+2.1%from $22.1M

Dec 31, 2025Mar 12, 2026

$0.05est. $0.05

+$0.00

CNY 37.2MAlpha Vantage

+33.4%from CNY 27.9M

Sep 30, 2025Nov 7, 2025

$0.03est. -$0.02

+$0.05

$32.7MSEC filing

+28.3%from $25.5M

Jun 30, 2025Aug 11, 2025

$0.00est. $0.03

-$0.03

$29.7MSEC filing

+17.9%from $25.2M

Mar 31, 2025May 9, 2025

$0.00est. $0.03

-$0.03

$22.1MSEC filing

-18.8%from $27.2M

Dec 31, 2024Mar 17, 2025

-$0.00est. $0.04

-$0.04

CNY 27.9MAlpha Vantage

+2.7%from CNY 27.1M

Income statement, 1 periods, all values in US dollars
USD	Sep 2026
What came in
RevenueTotal revenue	$32.9M
Cost of what it soldCost of revenue	$1.9M
Gross profit	$31.0M
What it spent
Research and development	$8.5M
Sales and adminSelling, general and administrative	$8.9M
Other operating costsOperating costs not itemised in the filing's summary	$15.1M
Total operating expenses	$32.5M
What was left
Operating profitOperating income	-$1.5M
Profit before tax	-$1.7M
TaxIncome tax expense	$733.0K
Net profitNet income	-$4.1M
EBITDAEarnings before interest, tax, depreciation, amortisation	-$1.7M

USD

Sep 2026

What came in

RevenueTotal revenue

$32.9M

Cost of what it soldCost of revenue

$1.9M

Gross profit

$31.0M

What it spent

Research and development

$8.5M

Sales and adminSelling, general and administrative

$8.9M

Other operating costsOperating costs not itemised in the filing's summary

$15.1M

Total operating expenses

$32.5M

What was left

Operating profitOperating income

-$1.5M

Profit before tax

-$1.7M

TaxIncome tax expense

$733.0K

Net profitNet income

-$4.1M

EBITDAEarnings before interest, tax, depreciation, amortisation

-$1.7M

Gyre Therapeutics Inc.

Smart money at a glance

What do analysts expect?

Questions about GYRE filings

Smart money on GYRE

Questions about GYRE filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 126.7% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Gyre Therapeutics Inc.

Smart money at a glance

What do analysts expect?

Questions about GYRE filings

Smart money on GYRE

Questions about GYRE filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 126.7% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Gyre Therapeutics Inc.

Overview

Questions about GYRE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Gyre Therapeutics Inc.

Overview

Questions about GYRE filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.